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Abstract
Sperm-associated antigen 5 (SPAG5) is an important driver of the cell mitotic spindle required for chromosome segregation and
progression into anaphase. SPAG5 has been identified as an important proliferation marker and chemotherapy-sensitivity
predictor, especially in estrogen receptor-negative breast cancer subtypes. Here, we report that SPAG5 is a direct target of miR-
10b-3p, and its aberrantly high expression associates with poor disease-free survival in two large cohorts of breast cancer
patients. SPAG5 depletion strongly impaired cancer cell cycle progression, proliferation, and migration. Interestingly, high
expression of SPAG5 pairs with a YAP/TAZ-activated signature in breast cancer patients. Reassuringly, the depletion of YAP,
TAZ, and TEAD strongly reduced SPAG5 expression and diminished its oncogenic effects. YAP, TAZ coactivators, and TEAD
transcription factors are key components of the Hippo signaling pathway involved in tumor initiation, progression, and
metastasis. Furthermore, we report that SPAG5 is a direct transcriptional target of TEAD/YAP/TAZ, and pharmacological
targeting of YAP and TAZ severely reduces SPAG5 expression. Collectively, our data uncover an oncogenic feedback loop,
comprising miR-10b-3p, SPAG5, and YAP/TAZ/TEAD, which fuels the aberrant proliferation of breast cancer.
Introduction
Breast cancer is the most frequent type of tumor and the
main cause of cancer-related death among women
worldwide [1]. Based on the expression of estrogen receptor
(ER), progesterone receptor (PgR), and ERBB2 (HER2),
breast tumors are classified as luminal A, luminal B, HER2,
and basal-like or triple-negative (TNBC), which exhibit
different tumor aggressiveness and response to therapy
[2–4]. It is well established that aberrant expression of
miRNAs, a class of short noncoding endogenous RNAs that
regulate gene expression by binding to the 3′-untranslated
regions of their target mRNAs, fosters cancer development
[5]. Several miRNAs have been reported to act as regulators
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of breast cancer development and progression and correlate
with the hormone receptor status [6].
Sperm-associated antigen 5 (SPAG5), primarily descri-
bed as a component of the mitotic spindle required for entry
into anaphase [7–12], acts as a driver oncogene in various
cancer types [13–17], including triple-negative breast can-
cer [18–20].
Advanced breast tumors frequently display increased
activity of the Hippo signaling pathway [21–23], whose
key players are the TEAD-transcriptional coactivator Yes-
associated protein (YAP) and the transcriptional coactivator
with a PDZ-binding domain (TAZ) [24]. Here, we report for
the first time that SPAG5 serves as a direct target of miR-
10b-3p. Accordingly, miR-10b-3p’s expression is sig-
nificantly anticorrelated to SPAG5’s transcript level. The
latter associates with poor survival in two different cohorts
of breast cancer patients, METABRIC and TCGA datasets.
Congruently, SPAG5 depletion reduces proliferation and
migration of breast cancer cell lines, while its ectopic
overexpression confers oncogenic properties to MCF-10A,
an untransformed mammary gland cell line. Importantly,
high expression of SPAG5 is linked to the transcriptional
signature of activated YAP/TAZ in breast cancer patients,
implying the involvement of YAP/TAZ in the oncogenic
activity of SPAG5. We further report that SPAG5 is a direct
transcriptional target of the YAP/TAZ/TEAD axis, such that
YAP/TAZ depletion diminishes SPAG5’s oncogenic
potential. Gratifyingly, pharmacological inactivation of
YAP and TAZ markedly reduced SPAG5 expression. In
aggregate, our findings uncover a transcriptional and post-
transcriptional network that sustains aberrant SPAG5
expression and contributes to breast cancer aggressiveness.
Materials and methods
CoSMic analysis using the METABRIC dataset
The METABRIC dataset contains 1286 primary breast
cancer tumors for which both mRNA https://ega-archive.
org/dacs/EGAC00001000484 [25] and miR https://ega-a
rchive.org/studies/EGAS00000000122 [26] expression data
were measured. The patients are from the 5 subtypes of
breast cancer: Her2+ (127 pt.), basal-like (209 pt.), luminal
A (479 pt.), luminal B (312 pt.), and normal-like (151 pt.).
We used CoSMic along with the METABRIC dataset
and miRanda predictions (http://www.ebi.ac.uk/enright-srv/
microcosm/htdocs/targets/v5/) [27].
CoSMic algorithm integrates gene expression measure-
ments of mRNAs and miRs taken from the same samples,
with sequence-based miR-target predictions, to improve the
reliability of miR-target predictions. The algorithm works
on each miR separately, and searches for a group of genes
with expression levels that are significantly anticorrelated
with the miR’s expression, and have high sequence-based
prediction scores. CoSMic provides for each miR a group of
genes that were identified as its predicted context-specific
targets and a corresponding P value for the significance of
this prediction.
Statistical analysis
Normalized miRNA and gene expression of breast cancer
patients was obtained from Metabric dataset and Broad
Institute TCGA Genome Data Analysis Center (2016):
TCGA data from Broad GDAC Firehose 2016_01_28 run.
Broad Institute of MIT and Harvard. Dataset. https://doi.
org/10.7908/C11G0KM9.
Statistical significance of the modulation of a gene
among subgroups of patients was inferred by Student’s T
test or ANOVA test.
Unsupervised hierarchical clustering was performed to
individuate a specific pattern of expression using the
Euclidean distance metric.
Survival and progression-free survival were evaluated by
Kaplan–Meier method and a log-rank test was used to
establish the statistical significance of the distance between
curves. High- and low- expression values for subgroups of
patients were assessed by calculating z scores of a single
gene or by the z scores of the mean value of a signature of
genes. The multivariate Cox proportional hazard regression
model was used to evaluate the impact of clinical variables
on the survival curves. MATLAB R2019b software was
used to perform the analyses.
Collection of breast cancer gene expression data
To investigate the correlation between SPAG5 expression
and metastasis-free survival, we used a collection of 3661
unique samples from 25 independent cohorts comprising
gene expression data of breast cancer samples annotated
with histological tumor grade and clinical outcome. The
collection was normalized and annotated with clinical
information as described in ref. [28].
Survival analysis
To identify two groups of tumors with either high or low
SPAG5 expression, we used the classifier described in
ref. [29]. Tumors were classified as “SPAG5 Low” if the
SPAG5-standardized expression was negative and as
“SPAG5 High” vice versa. To identify two groups of
tumors with either high or low YAP/TAZ signature, we
used the same classification rule on the YAP/TAZ signature
form [30]. Tumors were classified as “YAP/TAZ signature
Low” if the signature score was negative and as “YAP/TAZ
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signature High” if the signature score was positive. To
evaluate the prognostic value of SPAG5 expression, we
estimated, using the Kaplan–Meier method, the prob-
abilities that patients would remain free of metastasis. The
Kaplan–Meier curves were compared using the log-rank
(Mantel–Cox) test. P values were calculated according to
the standard normal asymptotic distribution. Survival ana-
lysis was performed in GraphPad Prism.
Signature scores
Signature scores have been obtained summarizing the
standardized expression levels of signature genes into a
combined score with zero means [29]. The values shown in
graphs are thus adimensional.
Cell lines and culture conditions
Human cell lines MDA-MB-231, MDA-MB-468, and
MCF-7 were maintained in Dulbecco’s Modified Eagle
Medium DMEM (Invitrogen–GIBCO, Carlsbad, CA, USA)
supplemented with 10% fetal bovine serum (FBS)
(Invitrogen–GIBCO), penicillin (100 U/ml), and strepto-
mycin (100 µg/ml). SUM-159PT human cell line
was maintained as DMEM/F12.GLUTAMAX (Invitrogen–
GIBCO, Carlsbad, CA, USA) supplemented with 10% fetal
bovine serum (FBS) (Invitrogen–GIBCO), 10 µg/ml Insulin
(Sigma, St Louis, MO, USA), penicillin (100 U/ml), and
streptomycin (100 µg/ml). MCF-10A human cell line was
maintained as DMEM/F12.GLUTAMAX (Invitrogen–
GIBCO, Carlsbad, CA, USA) supplemented with 5% horse
serum (HS) (Invitrogen–GIBCO), 10 µg/ml Insulin
(Sigma, St Louis, MO, USA), 20 ng/ml EGF, 0.5 µg/ml
hydrocortisone, penicillin (100 U/ml), and streptomycin
(100 µg/ml). All cell lines were obtained from ATCC and
cultured as monolayers at 37 C and 5% CO2.
Immunohistochemistry
Ten breast cancer and the correspondent nontumoral tissues
were randomly selected from 80 cases already evaluated for
miRNA profiles. The study was approved by the scientific
ethics committee from Regina Elena Cancer Institute (pro-
tocol number 5E/459/10).
Formalin-fixed paraffin-embedded BC specimens were
cut on SuperFrost Plus slides (Menzel-Glaser, Braunsch-
weig, Germany). Two-micron-thick paraffin-embedded
sections were stained with a streptavidin-enhanced immu-
noperoxidase technique (Supersensitive Multilink, Novo-
castra, Menarini Florence, Italy) in an automated autostainer
(Bond Max, Menarini) using the following reagents: anti-
SPAG5 polyclonal antibody (PoAb) 1:200, Bethyl
Laboratories, Inc. (Montgomery, TX). The pH 8 buffer
antigen-retrieval protocols were applied. Diaminobenzidine
(Menarini) was used as a chromogenic substrate.
The immunostaining was considered positive when at
least 10% of the neoplastic cells showed a distinct cyto-
plasmic and/or nuclear/cytoplasmic immunoreactivity. Two
investigators performed an evaluation of the immunohisto-
chemical results, blinded to all patient data, independently.
H score= [1× (% cells 1+ )+ 2× (% cells 2+ )+ 3× (%
cells 3+ )].
Immunocytochemistry and immunofluorescence
For immunocytochemistry assay, cells were seeded onto
glass coverslips (Paul Marienfeld, Lauda-Königshofen,
Germany) in six-well dishes (Corning Inc.) at 4 × 104 cells/
well in culture media, and fixed with 4% formaldehyde in
PBS for 15 min at room temperature. Cells were permea-
bilized with 0.25% Triton X-100 in PBS for 10 min. After
washing with PBS, the coverslips were incubated with
peroxidase inhibitor and then with anti-SPAG5 antibody
A301-512A Bethyl Laboratories, Inc. (Montgomery, TX)
diluted in 5% bovine serum albumin (BSA)/PBS for 2 h at
room temperature. Protein staining was revealed through
DAB enzymatic reaction, and nuclei were counterstained
with hematoxylin.
For immunofluorescence, cells were fixed and permea-
bilized as already described. Slides were blocked for 30 min
in 5% BSA/PBS at room temperature and then incubated
with an anti-SPAG5 antibody A301-512A Bethyl Labora-
tories (Montgomery, USA), anti-γ-tubulin sc-17787 (Santa
Cruz), according to the manufacturer’s instructions, in 5%
BSA/PBS overnight at +4 °C. Cells were incubated with
secondary antibody Alexa Fluor 594 (1:500, Thermo Fisher
Scientific) for 45 min. Nuclei were stained with DAPI
(Thermo Fisher Scientific).
Plasmids and transfections
For mature miR-10b-3p expression, we used Pre-miRNA
Precursor-Negative Control (Ambion), Pre-miRNA10b-3p
(Ambion), miRNA inhibitor negative control (Ambion),
and miRNA-10b-3p inhibitor (Ambion) at a final
concentration of 5 nM using Lipofectamine RNAi MAX
(Invitrogen) according to the manufacturer’s instructions.
MDA-MB-231, MDA-MB-468 SUM-159PT MCF-7, and
MCF-10A cells were transfected with siRNA of SPAG5:
siSPAG5 #1 AAGGAGUCUGAAACAGAAGAU siS-
PAG5 #2 AAGGCAGCAACAACUCAUCUC, siYAP
GACAUCUUCUGGUCAGAGA, siTAZ is a pool of two
independent siRNAs mixed in an equal amount of siTAZ#1
AAAGUUCCUAAGUCAACGU, and siTAZ#2 AGGUA
CUUCCUCAAUCACA and siTEAD GCAUUUGUAU
ACCGAAUAA at a final concentration of 100 pM using
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Lipofectamine RNAi MAX (Invitrogen) according to the
manufacture’s instructions. siGFP UUCAGC GUGUC
CGGGGAG was used as control. For stable overexpression
of SPAG5, MCF-10A cells were transfected with a plasmid
pcMV6, containing the complete open-reading frame of the
human SPAG5 transcript driven by the CMV promoter
(OriGene Technologies) using Lipofectamine 3000 (Invi-
trogen) according to the manufacturer’s instructions. No
difference between the efficiency of the transfection of
empty vector pcMV6 and pvMV6-SPAG5 plasmid was
assessed. Culture media containing G-418 A1720 (Sigma-
Aldrich) at final concentration of 0.1 µM, was used to select
individual clones that were screened for SPAG5 over-
expression by western blot analysis. After 3 months of
continuous culture in selection media containing G-418,
SPAG5 overexpression was unchanged.
FACS cell cycle analysis
For cell cycle analysis, cells were collected after 72 h from
selective depletion. Fixed cells were treated for 30 min with
RNase before PI addiction and analyzed with Guava
Easycyte 8HT flow cytometer equipped with Guava Soft
2.1 (Millipore) according to the manufacturer’s instructions.
BrdU-incorporation analysis
Cells were grown in complete medium with 10 µM of BrdU
for 4 h, washed with BSA/PBS, and fixed. After denatura-
tion, cells were treated with anti-BrdU primary antibody.
Then, permeabilized cells were labeled with fluorescent
secondary antibody and treated with propidium iodide
before FACS analysis according to the manufacturer’s
instructions.
Annexin V staining
Annexin staining was performed following Annexin V-
FITC Apoptosis Detection Kit protocol (eBioscence) [31]
according to the manufacturer’s instructions.
Luciferase assay
pMirTarget vector containing full length of 3′-UTR of the
human SPAG5 gene was purchased from OriGene (Ori-
Gene Technologies).
SPAG5 3′UTR mutant was made with the QuikChange
site-directed mutagenesis kit (Stratagene) using the fol-
lowing primers:




HEK-293 cells were transfected using Lipofectamine
2000 (Invitrogen) with pMiR-Target vector containing the
3′-UTR of SPAG5, together with Pre-miRNA Precursor-
Negative Control (Ambion) and Pre-miRNA10b-3p
(Ambion) or pMiR-Target vector from OriGene (OriGene)
with Pre-miRNA Precursor-Negative Control (Ambion) and
Pre-miRNA10b-3p (Ambion) in 24-well plates. Firefly and
Renilla luciferase activities were measured 48 h post
transfection using the Dual-Luciferase Reporter Assay
System (Promega) in the GloMax 96 Microplate Lumin-
ometer (Promega). Renilla luciferase was used to normalize
the firefly luciferase.
pGL3-SPAG5 657–884 and pGL3-SPAG5 2909–3084
were generated by cloning 227 bp and 175 bp, respectively,
from SPAG5 promoter in the SmaI- and XhoI-restriction
sites of pGL3-basic vector (Promega) using the following
primers:
pGL3-SPAG5 657–884 FW: ATTTCCCGGGGCACG
GACTCTTTCATCCA;
pGL3-SPAG5 657–884 RV: ATCTCTCGAGGCCTC
CCAAAGTGCTAGGAT;
pGL3-SPAG5 2909–3084 FW: ATTTCCCGGGTGGG
GTCGTTCATGACTGTA;
pGL3-SPAG5 2909–3084 RV: ATTTCTCGAGCTGCC
TCAGCCTCCTGAGTA;
MDA-MB-231 cells were transfected using Lipofecta-
mine 2000 (Invitrogen) with pGL3-basic vector, pGL3-
SPAG5 657–884, and pGL3-SPAG5 2909–3084, in 24-
well plates. Firefly and Renilla luciferase activities were
measured 72 h post transfection using the Dual-Luciferase
Reporter Assay System (Promega) in the GloMax 96
Microplate Luminometer (Promega). Renilla luciferase was
used to normalize the Firefly luciferase.
All reactions were performed in triplicate.
cDNA synthesis and qRT-PCR
One microgram of total RNA was reverse-transcribed at 37
°C for 60 min in the presence of random hexamers and
Moloney murine leukemia virus reverse transcriptase
(Invitrogen). Specific oligonucleotide primers for GAPDH
FW: GAGTCAACGGATTTGGTCGT, RV: GACAAGCT
TCCCGTTCTCAG, SPAG5 FW: ACTGAGAGTGA
TGTTCCTGGA, RV: CTAACTCCTTGTCAGAGCGC
were used for PCR analyses. Gene expression levels were
measured by quantitative real-time PCR using the SYBR
Green assay (Applied Biosystems) on a StepOne instrument
(Applied Biosystems). Small amounts of RNA (10 ng) were
reverse-transcribed using the TaqMan microRNA Reverse
Transcription Kit (Applied Biosystems) in a final volume of
10 µl using an ABI Prism 7000 Sequence Detection System
(Applied Biosystems). The PCR reactions were initiated
with a 10-min incubation at 95 °C followed by 40 cycles of
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95 °C for 15 s and 60 °C for 60 s. qPCR quantification
of miRNA expression was performed using TaqMan
MicroRNA® Assays (Applied Biosystems) according to the
manufacturer’s protocol. RNU6B was used as an endo-
genous control to normalize miRNA expression.
All reactions were performed in triplicate.
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Lysate preparation and immunoblotting analyses
Cells were lysed in buffer with 50 mM Tris-HCl, pH 8, 150
mM NaCl, 5 mM EDTA, and 1% NP-40 (Igepal AC-630).
Extracts were centrifuged at 14,000 rpm for 10 min to
remove cell debris. Protein concentrations were determined
by colorimetric assay (Bio-Rad). Western blotting was
performed using the following primary antibodies: rabbit
polyclonal anti-SPAG5 A301-512A Bethyl Laboratories,
Inc. (Montgomery, TX), rabbit polyclonal anti-SPAG5
antibody 60940 (Cell Signaling), rabbit monoclonal anti-
TAZ HPA007415 (Sigma-Aldrich), rabbit polyclonal
anti-YAP PA1-46189 (Invitrogen), mouse monoclonal anti-
TEF-1 610922 (BD Biosciences), rabbit monoclonal
anti-cyclin A [E23.1] (ab38) (Abcam), rabbit monoclonal
anti-cyclin B ab215436 (Abcam), mouse monoclonal anti-
cyclin D1 sc-8396 (Santa Cruz), mouse monoclonal
anti-cyclin D3 sc-56308 (Santa Cruz), rabbit monoclonal
anti-N-cadherin sc-8424 (Santa Cruz), mouse monoclonal
anti-Vimentin sc-6260 (Santa Cruz), mouse monoclonal
anti-tubulin ab56676 (Abcam), mouse monoclonal anti-
Gapdh sc-47724 (Santa Cruz), and rabbit monoclonal anti-
p21 2947 (Cell Signalling). Secondary antibodies used were
goat anti-mouse, goat anti-rabbit conjugated to horseradish
peroxidase (Amersham Biosciences, Piscataway, NJ, USA).
Immunostained bands were detected by the chemilumines-
cent method (Uvitec Alliance, Cambridge).
Cell treatments
In total, 105 breast cancer cell lines were plated in 60-mm
dishes. After 24 h, cells were treated with Dasatinib S5254
(Selleck Chemicals) at a final concentration of 0.05–0.1 µM,
Verteporfin S1786 (Selleck Chemicals) at a final concentra-
tion of 2 µM, or 50 µg/ml of Agave compound [32] (Aboca
Society) for 72 h. Mitomycin M4287 (Merck KGaA, Darm-
stadt, Germany) at a final concentration of 10 µg/ml was
added to the culture medium for incubation at 37 °C for 2 h.
Colony-formation assay
Breast cancer cell lines were grown at 70% confluence and
transfected with Pre-miRNA Precursor-Negative Control
(Ambion) and Pre-miRNA10b-3p (Ambion) or siRNAs
using Lipofectamine RNAi MAX (Invitrogen) according to
the manufacturer’s instructions. After 48 h, detached cells
were seeded at 500 cells for six-well dishes (Corning-
Costar, Tewksbury, MA, USA). Fresh media (25%) was
added every 3 days. After 7–10 days, colonies were stained
with crystal violet and colonies counted.
Cell proliferation assay
Cell proliferation was determined by viable cell counting.
We seeded 1 × 104 cells in 60-mm plates in duplicate and
grew for 96 h. Cell counting was performed after 24, 48,
and 72 h of mixing an aliquot of cells 1:1 with Trypan Blue
dye (Invitrogen).
Transwell migration assays
Transfected cells were detached and counted. A migration
assay was performed using a 24-well plate. We seeded 5 × 104
cells, in a volume of 500 µl of DMEM without FBS, in the
upper chamber with an 8-mm pore-size filter (BD Falcon,
Franklin Lakes, NJ, USA), while the bottom chamber of the
transwell was filled with 700 µl of DMEM with 10% FBS.
Cells were allowed to migrate for 24 h in a humidified
incubator at 37 °C and 5% CO2. Migrated cells, which had
attached to the outside of the filter, were visualized by staining
with DAPI (Sigma-Aldrich) and counted under a Zeiss LSM
510 laser-scanning fluorescence confocal microscope.
Cell viability assay
In all, 8 × 102 cells were seeded into 96-well plates. Cell
viability was assessed using ATPlite assay (Perkin Elmer,
Massachusetts, USA) according to the manufacturer’s
instructions.
Promoter analysis
FASTA sequences of human SPAG5 (NM 06461) promoter
(5000 bp upstream of the TSS) were downloaded from
UCSC Genome Browser online database and pasted into
LASAGNA-Search 2.0 to identify predicted transcription
factor-binding sites. TRANSFAC matrices were used for
the analysis.
ChIP experiments
We performed 1% formaldehyde cross-linking and ChIP
experiments as described [33].
The chromatin solution was immunoprecipitated with
mouse monoclonal anti-TEF-1 610922 (BD Biosciences),
YAP1 polyclonal antibody PA1-46189 (Invitrogen), and
Fig. 1 SPAG5 is overexpressed in breast cancer tissues and
anticorrelated with miR-10b-3p. A, B Heatmaps SPAG5 and miR-
10b-3p expression in METABRIC cohort (A) and in TCGA dataset
(B). C, D Boxplot SPAG5 expression in tumoral versus normal
breast tissues in METABRIC cohort (C) and in TCGA dataset (D).
E, F Boxplot SPAG5 expression in Lum-A, Lum-B, Her2, and basal-
like breast cancer histotypes in METABRIC cohort (E) and in the
TCGA dataset (F). G, H Kaplan–Meier plots show survival analysis of
breast cancer patients with low and high expression of SPAG5 in
METABRIC cohort (G) and in the TCGA dataset (H).
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rabbit polyclonal H4Ac 2594 (Cell Signaling). The immu-
noprecipitations were performed using Pierce ChIP-grade
Protein G magnetic beads (Thermo Fisher Scientific). The
immunoprecipitated and purified chromatin was subjected
to RT-qPCR. The promoter occupancy was analyzed by
RT-qPCR using the SYBR Green assay (Applied Biosys-
tems). Normalization was performed to the amount of input
chromatin.
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Results
MiR-10b-3p downregulation is anticorrelated to
SPAG5 expression in breast cancer tissues
We previously demonstrated that forced downregulation of
miR-10b-3p in breast cancer perturbed BUB1, PLK1, and
CCNA2 expression, hence accelerated tumor progression
[34]. Herein, we examined expression levels of miR-10b-3p
in two different cohorts of breast cancer patients, 1286 pri-
mary breast tumors from the METABRIC dataset, and 103
tumoral and nontumoral matched tissues from the TCGA
dataset (Supplementary Fig. 1A, B). In addition, using the
CoSMic algorithm [27] and the miRanda tool (http://www.
ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/), we iden-
tified 15 context-specific target genes in the METABRIC
dataset as significantly anticorrelated with miR-10b-3p
expression (Fig. 1A) [25, 26]. MiR-10b-3p was identified as
having a significant anticorrelation (P value= 9.86 × 10−10/q
value= 1.95 × 10−4), with 15 target genes (listed in the order
of significance) FOXM1, BUB1, EZH2, PLK1, CCNA2,
EXO1, ECE2, SPAG5, POP1, PSMD11, PUS1, CHEK1,
WDR4, EIF2C2, and LSM4 (Fig. 1B). Among them, we
focused on sperm-associated antigen 5 (SPAG5), a recently
described promoter of breast tumor growth [19] and a poor
prognosis marker of breast cancer [18]. Correspondingly,
SPAG5 is strongly expressed (t test P value= 4.4658e−12 and
t test P value= 3.2145 e−43) in breast cancer specimens
compared to nontumoural tissues, in both METABRIC and in
the TCGA dataset (Fig. 1C, D). Interestingly, SPAG5’s
expression is higher (ANOVA test P= 1.3655e−94 and
ANOVA test P= 1.3655e−94) in the Luminal B, HER2, and
basal-like breast cancer subtypes, as compared to the Luminal
A subtype (Fig. 1E, F). Moreover, SPAG5’s expression sig-
nificantly associated with shorter patient overall survival in
both datasets (Fig. 1G, H). In addition, SPAG5 expression
and miR-10b-3p levels were significantly anticorrelated
(Fig. 1A, B and Supplementary Fig. 1C, D). In conclusion,
our observations raised the possibility that miR-10b-3p
directly regulates transcripts encoding SPAG5, a gene asso-
ciated with the aggressive behavior of mammary tumors.
SPAG5 is a direct target of miR-10b-3p in breast
cancer cell lines
In order to assess the direct association of miR-10b-3p with
SPAG5 expression, we first located the miR-binding site on
the 3′UTR of SPAG5 using the TargetScan Prediction tool
(Supplementary Fig. 2A). Ectopic expression of miR-10b-
3p reduced mRNA (Fig. 2A–C and Supplementary
Fig. 2E–G) and protein levels of SPAG5 in four different
breast cancer cell lines: MDA-MB-231, MDA-MB-468,
MCF-7, and SUM-159PT (Fig. 2B–D and Supplementary
Fig. 2B, C, F–H), respectively, as well in MCF-10A, an
untransformed breast cell line (Fig. 2E, F and Supplemen-
tary Fig. 2D). Conversely, loss of function of miR-10b-3p
by using a specific miRNA inhibitor released SPAG5
transcript (Fig. 2A–C) and protein expression in both MDA-
MB-231 and MDA-MB-468 breast cancer cell lines
(Fig. 2B–D and Supplementary Fig. 2B, C) and in
MCF-10A cells (Fig. 2E, F and Supplementary Fig. 2D).
Functionally, the clonogenic ability of MDA-MB-231
breast cancer cell line was slightly increased by inhibition
of miR-10b-3p expressions, while a more evident effect was
seen in MCF-10A cells (Fig. 2G, H).
We also found that in matched breast tumor and non-
tumor tissues, lower levels of miR-10b-3p were associated
with higher SPAG5 protein expression (Fig. 2I upper and
lower panels). Next, to determine whether the predicted
binding site within 3′UTR of SPAG5 is directly targeted by
miR- 10b-3p, we performed dual Luciferase reporter assay
by transfecting cells with plasmids harboring either wild-
type SPAG5 or SPAG5 with a deletion at positions
174–176 in the 3′UTR. MiR-10b-3p ectopic expression
suppressed luciferase reporter activity of wild-type SPAG5,
while it was not decreased in cells transfected with SPAG5
harboring the indicated 3′UTR deletion, see Fig. 2J. Taken
together, these results validate that SPAG5 serves as a direct
target of miR-10b-3p in breast cancer cells.
Depletion of SPAG5 expression impairs proliferation
and migration of breast cancer cell lines
To assess the activity of SPAG5, we performed loss-of-
function assays using siRNA-mediated targeting of SPAG5 in
Fig. 2 miR-10b-3p affects SPAG5 expression by binding on
3’UTR. A, C, E qPCR expression level of SPAG5 in MDA-MB-231
(A), MDA-MB-468 (C) breast cancer cell lines, and in MCF10A-
untransformed breast cell lines (E) assessed by quantitative PCR after
48 h from mimic-10b-3p, miR-10b-3p inhibitor, and negative control
transfection. Histograms report the means and P value from three
independent experiments. B, D, F Immunocytochemistry of positive
SPAG5 expression in MDA-MB-231 (B), MDA-MB-468 (D) breast
cancer cell lines, and in MCF10A-untransformed breast cell lines after
48 h from mimic-10b-3p, miR-10b-3p inhibitor, and negative control
transfection. G, H Clonogenic assay of MDA-MB-231 (G) and MCF-
10A-untransformed breast cell lines (H) transfected with miR-10b-3p
inhibitor and negative control for 48 h before seeding at clonal density.
I Immunohistochemistry of SPAG5 expression in a representative
matched breast tumor and nontumoral tissues. In the lower panel, the
heatmap shows expression levels of miR-10b-3p and SPAG5 for each
tumor tissue. SPAG5 level was calculated using H score. miR-10b-3p
expression was assessed by qRT-PCR. J Luciferase assay expression
vectors carrying a luciferase reporter followed by the wild-type or
mutated 3′-UTR regions of SPAG5 were transfected in HEK-293T
cells in the presence of mimic-10b-3p and negative control. Normal-
ized luciferase-activity values and P value from three independent
experiments are shown (*P value <0.05; **P value <0.001).
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four different breast cancer cell lines: MDA-MB-231, MDA-
MB-468, MCF-7, and SUM-159PT. As shown in Fig. 3A–C
and D–F and in Supplementary Fig. 3A–D, breast cancer cell
proliferation and clonogenicity were significantly reduced in
siSPAG5-transfected cells compared with siGFP (control)-
transfected cells. MDA-MB-468 and MDA-MB-231 breast
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cancer cells depleted for SPAG5 protein expression accu-
mulated preferentially in the G2 phase of the cell cycle
(Supplementary Fig. 3G). This paired with the increased
levels of the CDK inhibitor p21 (Fig. 3B and E and Sup-
plementary Fig. 3C–F). Because high SPAG5 expression
associates with shorter metastasis-free survival in breast can-
cer patients (Fig. 3G), we determined the effect of SPAG5 on
breast cancer cell migration. To this end, we carried out
transwell assays that employed MDA-MB-231 and MDA-
MB-468 cell lines, which were pretreated with siRNAs in a
way that depleted SPAG5 expression. As shown in Fig. 3H, I,
siSPAG5-transfected cells markedly reduced migration abil-
ity. This effect appears to be uncoupled from cell proliferation
rate as evidenced by mitomycin treatment (Fig. 3H, I). In
addition, in both MDA-MB-231 cells and in MDA-MB-468
cells, the expression of vimentin and N cadherin declined
upon SPAG5 depletion (Supplementary Fig. 3H, I). Alto-
gether, these findings suggest that SPAG5 downregulation,
using RNA interference, can retard cell proliferation, migra-
tion, and EMT.
SPAG5 overexpression confers oncogenic potential
to MCF-10A cells
To further investigate the oncogenic role of SPAG5 in
breast cancer, we set up its stable overexpression in MCF-
10A cells. We isolated stably transfected cell clones over-
expressing SPAG5 (Supplementary Fig. 4A). The efficiency
of colony formation was significantly (t-test P= 7.92 e−05)
increased for MCF-10A cell clones overexpressing SPAG5
compared to control cells (Fig. 4A and Supplementary
Fig. 4B). In addition, we investigated the impact of either
SPAG5 depletion (Fig. 4B and Supplementary Fig. 4C) or
ectopic expression of miR-10b-3p on MCF-10A/SPAG5
cell clones (Fig. 4C and Supplementary Fig. 4D). Clear
reductions in the number of colonies were revealed under
both experimental conditions, as compared to control cells
(Fig. 4B, C). To elucidate the oncogenic activity of SPAG5,
we analyzed several cell cycle regulators, namely cyclin A,
B, D1, and D3 in MCF-10A cells overexpressing SPAG5.
Consistently, elevated levels of all four cyclins were
observed in MCF-10A/SPAG5 clones compared to control
cells (Fig. 4D). Furthermore, immunostaining of the cellular
proliferation marker Ki-67 [35, 36] was strongly increased
in clones overexpressing SPAG5 (Fig. 4E).
SPAG5 was first described as a dynamic regulator of the
mitotic spindle, chromosome segregation, and mitotic
progression [7, 8, 10, 11, 37]. It has been reported that
SPAG5 interference exerts no effect on the distribution and
morphology of mitotic microtubules rather the generation
of multipolar and highly disordered mitotic spindles, which
drove growth arrest [8]. Accordingly, γ-tubulin staining
highlighted large amounts of mitotic cells in MCF-10A
cells overexpressing SPAG5 and no perturbation of the
spindle microtubules; instead, SPAG5 depletion affected
chromosome alignment and impaired mitosis (Fig. 4F and
Supplementary Fig. 4J). Likewise, depletion of SPAG5 in
the SUM-159PT triple-negative breast cancer cell line
markedly reduced cell cycle-associated proteins, such
as cyclin A, cyclin B (Supplementary Fig. 4E), and the
cellular proliferation marker Ki-67 (Supplementary
Fig. 4F), as well as counteracts mitotic spindle formation
(Supplementary Fig. 4G).
Cell cycle analysis of different MCF-10A/SPAG5-over-
expressing clones and control cells evidenced active DNA
synthesis and increased S-phase fraction of proliferating
cells (Fig. 4G, H). Viability assay further validated the
oncogenic potential of SPAG5, which was counteracted
either by miR-10b-3p overexpression or by SPAG5 deple-
tion (Fig. 4I, J) in line with the results from SUM-159PT
triple-negative breast cancer cell line (Supplementary
Fig. 4H, I). Notably, depletion of SPAG5 halted the pro-
liferation and cell cycle progression reduced de novo DNA
synthesis, and increased the apoptotic rate of MCF-10A/
SPAG5 clones (Fig. 4K–N).
Taken together, these results highlight an important role
for SPAG5 as a regulator of cell cycle progression and
proliferation.
The transcriptional axis YAP/TAZ/TEAD controls
SPAG5 expression in breast cancer cells
The involvement of the Hippo pathway in cancer occurrence,
especially deregulation in breast cancer [23, 38–40], is well
established. Importantly, elevated expression of YAP/TAZ
signature correlates with high histological grade, enrichment
of stem cells, metastasis, and resistance to Taxol [22, 41].
Intriguingly, high levels of SPAG5 transcript expression in
breast cancer patients exhibit a statistically significant asso-
ciation with elevated YAP/TAZ signature mainly enriched for
Fig. 3 SPAG5 depletion affects proliferation, clonogenicity, and
migration of breast cancer cells. A–D Cellular growth curves of
MDA-MB-231 (A) and MDA-MB-468 (D) breast cancer cell lines
determined by counting dye method after 24–48–72 h from siGFP and
siSPAG5 tranfection. B–E Western blot with SPAG5 and p21 anti-
body of whole-cell lysates of MDA-MB-231 (B) breast cancer cell
lines and cleaved-PARP and caspase 3 antibodies of whole-cell lysates
of MDA-MB-468 (E) breast cancer cell lines harvested after 48 h from
siGFP or siSPAG transfection. C–F Clonogenic assay of MDA-MB-
231 (C) and MDA-MB-468 (F) breast cancer cell lines transfected
with siGFP and siSPAG5 for 48 h before seeding at clonal
density. G Kaplan–Meier plots show metastasis-free survival analysis
of breast cancer patients with low and high expression of SPAG5.
H–I Migration-assay histograms show the migrated cell count from
MDA-MB-231 and MDA-MB-468 breast cancer cell lines determined
by transwell assay after 72 h from siGFP or siSPAG5 transfection (H)
and treated with 10ug/ml of mitomycin (I) (*P value <0.05;
**P value <0.001).
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target genes involved in cell cycle regulation as from
Zanconato et al. [42] (Fig. 5A). No statistically significant
association was found with YAP/TAZ signature from
Cordenonsi et al. whose gene target composition is broader
than that of Zanconato et al., and not specifically enriched
for cell cycle genes [30] (Fig. 5B). Furthermore, SPAG5
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expression levels associate with known cell cycle-enriched
gene signatures, such as from MsigDB KEGG pathway,
E2F2, and E2F3 target gene signatures (Fig. 5C–E) [43].
Collectively, these data indicated SPAG5 as a YAP/TAZ cell
cycle-related target gene.
Second, we depleted (using siRNAs) the expression of
three main effectors of the pathway, YAP, TAZ, and
TEAD, in MCF-10A cells stably overexpressing SPAG5,
and in three different triple-negative breast cancer cell lines,
MDA-MB-231, MDA-MB-468, and SUM-159PT. Reas-
suringly, SPAG5 transcripts were significantly reduced 48 h
after siRNA transfection (Fig. 5F, H–J), while SPAG5
protein declined 24 h later (Fig. 5G, I, K and Supplementary
Fig. 5A). No significant perturbation of miR-10b-3p levels
was attested (Supplementary Fig. 5B, C), suggesting direct
transcriptional control of SPAG5 promoter by TEAD, YAP,
and TAZ.
SPAG5 is a direct transcriptional target of TEAD
Currently, the transcriptional regulation of SPAG5 is poorly
understood. Using the LASAGNA algorithm (Length-
Aware Site Alignment Guided by Nucleotide Association),
we searched for TEAD1-binding sites on the SPAG5 pro-
moter (Fig. 6A). To validate the in silico analysis for
TEAD- binding sites on SPAG5 promoter, we performed
ChIP assays in MDA-MB-231 following depletion of
TEAD expression (Supplementary Fig. 6A, B). CTGF, a
canonical transcriptional target of the Hippo pathway, was
used as a positive control (Supplementary Fig. 6C, D).
These assays found a significant enrichment of TEAD and
YAP recruitment on selected regions of SPAG5 promoter
(Fig. 6B, C, E, F, and Supplementary Fig. 6E, F, H, I). This
paired with increased Histone 4 acetylation, a marker
of transcriptionally active chromatin (Fig. 6D, G and Sup-
plementary Fig. 6G–J). Accordingly, TEAD depletion
(Supplementary Fig. 6A, B) markedly reduced both TEAD
and YAP recruitment onto the SPAG5 promoter and the
histone acetylation of the selected regions (Fig. 6B–G and
Supplementary Fig. 6E–J).
To further establish the transcriptional control of
TEAD on the SPAG5 promoter, we performed transacti-
vation assays. Promoter regions encompassing TEAD-
binding sites were cloned in front of a luciferase gene
reported (pGL3-SPAG5 657–884 and pGL3-SPAG5
2909–3084). This experimental approach revealed that
the depletion of TEAD expression can reduce SPAG5
promoter activity cloned regions (Fig. 6H), and this was
further strengthened by YAP codepletion. Collectively,
these findings show that SPAG5 is a direct transcriptional
target of TEAD.
Pharmacological targeting of YAP/TAZ impairs
SPAG5 oncogenic activity in triple-negative breast
cancer cells
The advanced anticancer therapies inhibiting YAP stabili-
zation, nuclear localization, and interaction with TEAD bear
the therapeutic potential for tumors with aberrant Hippo
activation [44]. To directly examine this prediction, we
tested whether the clinically approved YAP and TAZ
inhibitors, Dasatinib and Verteporfin, can affect the tran-
scriptional effect of YAP-TAZ and TEAD on SPAG5
promoter fragments. Indeed, we found that increasing doses
of Dasatinib and Verteporfin reduced pGL3-SPAG5
657–884 and pGL3-SPAG5 2909–3084 promoter frag-
ments measured as luciferase activity (Fig. 6I, J). Of note,
treatment of MDA-MB-231 breast cancer cells and
MCF-10A cells stably overexpressing SPAG5 with Dasa-
tinib and Verteporfin reduced SPAG5 protein level in a
dose-dependent manner (Fig. 6I, J lower panel and Sup-
plementary Fig. 6L, N, O) and affected their respective
colony-forming ability (Supplementary Fig. 6K–M).
Yet another potential drug, Agave, is a natural compound
with antimicrobial, pro-apoptotic, immunomodulatory,
antiproliferative, and anti-migratory properties. We pre-
viously reported that Agave exerts its anticancer activity in
part by impairing YAP’s and TAZ’s pro-tumorigenic
activities, both transcriptionally and post transcriptionally
[32]. Accordingly, we tested whether treatment with Agave
Fig. 4 Ectopic expression of SPAG5 confers tumorigenic potential
to untransformed MCF-10A cells. A–C Clonogenic assay. Repre-
sentative micrographs of colonies formed by MCF-10A cells stably
overexpressing either pcMV6 or SPAG5-expression vector (A)
transfected with siGFP and siSPAG5 (B), mimic-10b-3p, and negative
control (C) for 48 h before seeding at clonal density. Column graphs
show colony count and P value from three independent experiments.
D Western blot with SPAG5, cyclin A, cyclin B, cyclin D1, and cyclin
D3 of whole-cell lysate of MCF-10A cells stably overexpressing either
pcMV6 or SPAG5 (left panel) and MCF-10A cells stably over-
expressing SPAG5 transfected with siGFP or siSPAG5 (right panel).
E Immunocytochemistry of positive Ki-67 expression in MCF-10A
cells stably overexpressing SPAG5 transfected with siGFP or siS-
PAG5. F Percentage of mitotic cell: the graph shows the percentage of
mitotic cells in MCF-10A cells stably overexpressing either pcMV6
and SPAG5 transfected with siGFP and siSPAG5. G Cell cycle ana-
lysis of MCF-10A cells stably overexpressing either pcMV6 or
SPAG5-expressing vector assessed by flow-cytometry assay. H BrdU
staining of MCF-10A cells stably overexpressing either pcMV6 or
SPAG5. I–J Viability assay of MCF-10A cells stably overexpressing
SPAG5 transfected with siGFP or siSPAG5 (I) and mimic-10b-3p and
negative control (J). K Cell cycle analysis of MCF-10A cells stably
overexpressing SPAG5 transfected with siGFP or siSPAG5 assessed
by flow-cytometry assay. L BrdU staining of MCF-10A cells
stably overexpressing SPAG5 transfected with siGFP or siSPAG5.
M Annexin V staining of MCF-10A cells stably overexpressing
SPAG5 transfected with siGFP or siSPAG5. N Western blot cleaved-
PARP level in MCF-10A cells stably overexpressing SPAG5 trans-
fected with siGFP or siSPAG5. Data are presented as the mean of three
independent replicates (*P value <0.05; **P value <0.001).
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Fig. 5 YAP/TAZ signature score in high and low SPAG5 breast
cancer samples. A SPAG5 expression in YAP/TAZ signature from [42].
B SPAG5 expression and YAP/TAZ signature from ref. [30]. C SPAG5
expression in cell cycle signature from MsigDB KEGG. D SPAG5
expression in E2F3 signature from ref. [43]. E E2F signature in MsigDB
Hallmark. Unpaired t-test P value<0.0001. Selective depletion of YAP.
TAZ, TEAD reduces SPAG5 expression. F, H, J qPCR expression level
of SPAG5 in MCF-10A cells stably overexpressing SPAG5 (F) in
MDA-MB-231 (H) and in MDA-MB-468 (J) assessed by quantitative
PCR after 48 h from siGFP, siYAP, siTAZ, and siTEAD transfection.G,
I, K Western blot shows SPAG5 protein level in MCF-10A cells stably
overexpressing SPAG5 (G), in MDA-MB-231 (I) and in MDA-MB-468
(K) after 48 h from siGFP, siYAP, siTAZ, and siTEAD transfection
(*P value <0.05; **P value <0.001).
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can affect SPAG5 expression in MDA-MB-231 and in
MDA-MB-468 breast cancer cell lines. Indeed, we found
that Agave markedly reduced SPAG5 mRNA expression
(Supplementary Fig. 6P–R) and protein expression (Sup-
plementary Fig. 6Q–S) in both breast cancer cell lines.
Being a natural compound with ascertained multitargeting
activity, Agave might also impact on SPAG5 expression
triggering additional signaling pathways than YAP/TAZ/
TEAD axis modulation [32].
Collectively, these findings lend further support to the
role played by YAP and TAZ in the control of SPAG5
expression.
V. Canu et al.
The combination of YAP signature and SPAG5
expression predicts breast cancer mortality
In order to support the independent role of YAP-TAZ-
TEAD axis and SPAG5 in breast cancer development, we
conducted an analysis of data from the METABRIC dataset.
METABRIC is a large- cohort prospective study of very
well molecularly characterized breast cancer cases [25]. As
a first step, we performed univariate analysis to test whether
YAP signature and SPAG5 expression were actually prog-
nostic factors for disease-specific survival. To this end, we
used the whole Metabric dataset (N= 1969 patients) and we
confirmed YAP signature and SPAG5 as prognostic factors
for breast cancer (Table 1). Subsequently, in the same
Metabric cohort (N= 1969 patients), we conducted a Cox
multivariate analysis to control the results for potential
confounding factors, and we observed that both YAP sig-
nature and SPAG5 were independent prognostic factors
after adjusting for T, N, stage, hystotype, age, and meno-
pausal state (Table 1). In the second step, we subdivided
Metabric patients into four groups: YAPlow (expression)/
SPAG5low (expression), YAPhigh/SPAG5high, YAPhigh/
SPAG5low, and YAPlow/SPAG5high and found that YAPhigh/
SPAG5high group exhibited statistically significant shorter
disease-specific survival when compared with the three
other selected groups of Metabric patients (Fig. 7A and
Table 2). In the third step, we considered in the analysis
only those groups of patients characterized by concordant
YAP signature and SPAG5 expression (e.g., YAPhigh/
SPAG5high and YAPlow/SPAG5low, N= 996 patients). This
strategy allowed us to find a statistically significant and
direct correlation between the two variables for a Pearson’s
R= 0.61 (P= 7.6E–104). We also observed that between
the group YAPhigh/SPAG5high and the group YAPlow/SPA-
G5low, there was the highest difference in disease-specific
survival (log-rank test P= 1.9×E–09) being the first group
characterized by the shortest survival (Fig. 7A). We then
analyzed the expression of miR-10b-3p in relation to both
YAP signature and SPAG5 expression. In this section of
analyses, we selected from the METABRIC breast cancer
dataset, the whole group of cases for which data on SPAG5
expression, YAP signature, and miR- 10b-3p expressions
were available at the same time from the same breast cancer
cases. In order to understand the miR-10-3p expression in
relation to both SPAG5 and YAP signature, we then sub-
divided again the whole group (N= 1279) into the four
different categories as before, characterized by a different
mode of expression of SPAG5 and YAP signature: (1)
YAPhigh/SPAG5high and (2) YAPlow/SPAG5low (represent-
ing 1 and 2 the two concordant categories); (3) high
YAPhigh/SPAG5low and (4) YAPlow/SPAG5high (represent-
ing 3 and 4 the two discordant categories). In Fig. 7B, C, we
described the observed association between the expression
of SPAG5, YAP signature, and miRNA10b-3p expression
through the different categories and different analytical
steps. In Fig. 7B, we observed the heatmap describing miR-
10b-3p down-/upregulation in relation to SPAG5, YAP
signature expression by the four categories described above.
The graph on the extreme right represents the concordant
group YAPhigh/SPAG5high. Here, the highest level of
SPAG5 expression correlates with a strong downregulation
of miR-10b-3p corroborating the anticorrelation of miR-
10b-3p and SPAG5 expression. Concomitantly, also, YAP
signature exhibited its highest level of expression
(Fig. 7BIV). The second graph from the right shows again
the SPAG5 high expression accompanied with again
miR-10-3p downregulation, despite a low expression of
YAP signature corroborating the previous evidence of a
direct anticorrelation between SPAG5 and miR-10-3p
(Fig. 7BIII). In the third graph from the right, we
observed the second concordant category (SPAG5low/
YAPlow) in which, this time, miR-10b-3p tends to become
less downregulated than before, supporting again an initial
anticorrelation effect of miR-10b-3p on SPAG5, which
appears to be independent of YAP signature expression
(Fig. 7BII). Finally, in the fourth graph, the more potent
expression of miR-10-3p corresponds to a very low
expression of SPAG5 in spite of YAP signature that now is
high, indicating a potentially strongest modulation on
SPAG5 of miR- 10b-3p in comparison with YAP expres-
sion (Fig. 7BI). The last heatmap further confirms the
analytical evidence of an independent effect between YAP
signature and miR-10b-3p on SPAG5 modulation.
Figure 7C also shows the different distribution by histo-
types (luminal, Her2, basal-like, and normal-like) of the
four concordant/discordant categories. The hystotype char-
acterization supports, as expected, the highest mortality for
the more aggressive breast cancer-concordant category
Fig. 6 TEAD and coactivator YAP directly bind the SPAG5 pro-
moter. A Schematic representation of the SPAG5 promoter with the
putative TEAD-binding sites (LASAGNA Search 2.0). The promoter
regions 657–884 and 2909–3084 were amplified and cloned into pGL3
vector. B, C, E, F Chip analysis of the TEAD and YAP binding on
SPAG5 promoter in MDA-MB-231 cell line after TEAD interference
detected by qRT-PCR analysis. D–G Transcriptional active chromatin
on SPAG5 promoter evidenced by anti-H4-Acetylate antibody. Data
are shown as the mean of three independent replicates with the a
relative P value. H–J Luciferase assay pGL3 vector carrying SPAG5
657–884 and SPAG5 2909–3084 promoter regions was transfected in
MDA-MB-231 cell line after YAP and/or TEAD interference.
H MDA-MB-231 cell lines were treated with 0.05–0.1 µM of Dasa-
tinib (I) or with 2 µM of Verteporfin (J) and transfected with pGL3
vector carrying SPAG5 657–884 and SPAG5 2909–3084 promoter
regions. Normalized luciferase-activity values and P value from three
independent experiments are shown. In the lower panel, western blot
shows SPAG5 expression after 0.05–0.1 µM of Dasatinib (I) or with 2
µM of Verteporfin (J) treatments. (ns nonsignificant; *P value <0.05;
**P value <0.001).
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(SPAG5high-YAPhigh), at high prevalence in basal-like
tumors (Fig. 7C). Figure 7D shows quantitatively the
expression of miR-10b-3p by the four different groups, with
the highest statistically significant difference for the dis-
cordant category SPAG5low-YAPhigh.
Collectively, these results indicate the strong inter-
connection within the network of three prognostic factors,
SPAG5, YAP, and miR-10b-3p expression that also pairs
with the prevalence of different cell populations in the
identified breast cancer subtypes.
Discussion
It is widely accepted that breast cancer is a heterogeneous
disease, which comprises several clinically and morpho-
logically distinct subtypes, differing in genetic and epi-
genetic alterations that strongly affect diagnosis, treatment,
and prognosis. Depicting how tumor cells are able to grow
and spread to distant sites will surely contribute to effi-
caciously treat breast cancer. miRNA engagement in the
onset of the malignant state through the tumor progression
and metastasis is now extensively ascertained [45, 46].
Here, we identified SPAG5 as a novel miR-10b-3p target
gene. Interestingly, high expressions of SPAG5 associate
with lower expression of miR-10b-3p in both METABRIC
and TCGA breast cancer datasets and correlate with lower
disease-specific survival. Aberrant SPAG5 expression has
been reported in several cancer types. This appears to be
triggered by Ch.17q11.2 locus gain or amplification [18].
SPAG5 knockdown significantly downregulated the
activation of Akt signaling. Indeed, downregulation of
miR-363-3p allows SPAG5 to exert its oncogenic activity
initiating PI3K/AKT pathway via CEP55 interaction in
hepatocellular carcinoma [13]. PLK1 is a direct target of
miR-10b-3p [34], and it acts as an upstream kinase needed
for SPAG5 phosphorylation and kinetochore organization
[47]; our results suggest that restoring miR-10b-3p
expression might contribute to properly tune mitotic
spindle assembly in breast cells. Altogether, these findings
indicate that downregulation of miR-10b-3p leads to
aberrant cell proliferation by means of unleashing a
coordinated network of cell cycle regulators, which
impinge on diverse signaling pathways governing cell
proliferation. We also document that SPAG5 ectopic
expression confers upon untransformed MCF-10A breast
cells the ability to form colonies, and, concordantly,
SPAG5 depletion markedly reduces proliferation, clono-
genicity, and cancer cell migration, as well as affects the
main EMT markers, such as vimentin and N cadherin
(Fig. 3H, I and Supplementary Fig. 3H, I). Interestingly,
high expression of SPAG5 associates with shorter
metastasis-free survival in breast cancer patients (Fig. 3G).
These findings provide further evidence confirming the
oncogenic role of SPAG5 in breast cancer, as well as in
other tumor types.
Little is known about SPAG5’s transcriptional regula-
tion. Intriguingly, by integrating specific genes, miRNA
expression patterns, and transcriptional profiles, we found
that breast cancer patients with high SPAG5 expression
exhibit an activated YAP/TAZ signature, implying that
aberrant activation of the two key transducers either
independently or dependently from their role in the Hippo
pathway enhances SPAG5’s oncogenic activity. Accord-
ingly, the depletion of either YAP or TAZ significantly
reduced SPAG5 transcript and protein expression. Inter-
estingly, this effect was also highlighted upon depletion of
the TEAD transcription factor, suggesting that SPAG5
could serve as a breast cancer target within the oncogenic
transcriptional axis YAP/TAZ/TEAD. Specifically, we
found that YAP and TEAD binding-to-binding sites were
mapped in SPAG5’s promoter paired with increased his-
tone acetylation, a marker of active transcription. Notably,
the critical involvement of the YAP/TAZ/TEAD axis as a
broad transcriptional regulator of breast cancer tumor-
igenesis has previously been reported [22, 23, 48–52], but
Table 1 YAP signature and
SPAG5 are independent
prognostic factors for breast
cancer.
N patients= 1969 Cox univariate Cox multivariate
HR [95% CI] P value HR [95% CI] P value
YAP signature 1.26 [1.16–1.36] 8.9e–09 1.25 [1.15–1.35] 4.026e–08
SPAG5 1.22 [1.13–1.31] 9.47e–08 1.21 [1.12–1.29] 5.37e–07
Cox-univariate and Cox-multivariate analysis for YAP signature and SPAG5 expression on breast cancer
Metabric dataset (N= 1969 patients).
Table 2 Prognosis of highly correlated breast cancer patients with high
levels of YAP signature and high levels of SPAG5.
N patients= 996 Cox multivariate





Cox-multivariate analysis of breast cancer Metabric patients with high
and low levels of YAP signature and SPAG5 adjusted for T, N, stage,
hystotype, age, and menopausal state (N= 996 patients).
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the identification of transcriptional targets with specific
activities in breast cancer still needs to be elucidated.
Intense research efforts have been focused on the
pharmacological targeting of the YAP/TAZ/TEAD
transcriptional axis in human cancers. Diverse compounds
acting either on YAP/TAZ nuclear localization or redu-
cing protein expression have been identified and hold
promise for clinical applications.
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Among other experimental approaches, Dasatinib and
Verteporfin were shown to strongly impair YAP/TAZ co-
transcriptional activities in breast cancer cell lines.
Accordingly, we found that the treatment of breast cancer
cell lines with either Dasatinib or Verteporfin and with
extracts of Agave reduced SPAG5 expression. Dasatinib
has recently been challenged in a phase II trial on unse-
lected advanced triple-negative breast cancer patients,
exhibiting limited activity as a single agent [53]. Interest-
ingly, there are active clinical trials with Verteporfin for
breast cancer and other solid tumors (NCT02872064,
NCT03033225, and NCT04590664). Based on its pre-
viously reported role as a determinant of drug response in
breast cancer patients, along with its contribution to an
improved determination of breast cancer subtypes, SPAG5
might hold the potential to be a promising biomarker, which
identifies patients who could benefit from drugs targeting
YAP/TAZ activities, either alone or in combination with
other treatments.
In summary, our findings identify a novel transcrip-
tional and post-transcriptional network, which leads to
aberrant activation of SPAG5 in breast cancer. The timing
of this network might be differently regulated within the
diverse breast cancer subtypes. The uncovered scenario
features both early (post-transcriptional) and late
(transcriptional) steps of tumorigenesis, fine resolution of
which would allow designing effective therapeutic
approaches [45] (Fig. 7E).
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